Episodes 31-45 of 746
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
Oncology and HematologyAdjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
Oncology and HematologyPatient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
KEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
Oncology and HematologyKEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Oncology and HematologyCohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Amivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
Oncology and HematologyAmivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
Advancing Biomarker Testing Strategies in Upper GI Cancers: From PD-L1 to FGFR2b
Project Oncology®Advancing Biomarker Testing Strategies in Upper GI Cancers: From PD-L1 to FGFR2b
- advertisement
Evaluating Patient and Clinician-Reported Responses to Axatilimab in cGVHD
Project Oncology®Evaluating Patient and Clinician-Reported Responses to Axatilimab in cGVHD
Advancing Precision Medicine in NSCLC: Real-World Impact of the PREDICT Initiative
Project Oncology®Advancing Precision Medicine in NSCLC: Real-World Impact of the PREDICT Initiative
Impacts of Multidisciplinary Tumor Boards and Surgery Integration on NSCLC Survival
Project Oncology®Impacts of Multidisciplinary Tumor Boards and Surgery Integration on NSCLC Survival
AAT C-Terminal Peptides Show Independent Prognostic Value in Early-Stage NSCLC
Project Oncology®AAT C-Terminal Peptides Show Independent Prognostic Value in Early-Stage NSCLC
Early Liquid Biopsy in Advanced Lung Cancer: Real-World Data Suggest Targeted Gains
Project Oncology®Early Liquid Biopsy in Advanced Lung Cancer: Real-World Data Suggest Targeted Gains
Managing Chronic Graft-Versus-Host Disease with CSF1R Inhibition
Project Oncology®Managing Chronic Graft-Versus-Host Disease with CSF1R Inhibition
- advertisement
Advances in Disease-Modifying and Curative Therapies for Sickle Cell Disease
Project Oncology®Advances in Disease-Modifying and Curative Therapies for Sickle Cell Disease
CRISPR in Sickle Cell: Transforming Care Through Gene Editing
Project Oncology®CRISPR in Sickle Cell: Transforming Care Through Gene Editing
Evaluating Gene Therapy for Sickle Cell Disease: Advantages and Barriers
Project Oncology®Evaluating Gene Therapy for Sickle Cell Disease: Advantages and Barriers
